AT

Alasdair Thong

Founding Partner at Selvedge Venture

London, England

Overview 

Alasdair Thong, a London-based professional in biotechnology, deeptech, and healthcare, is currently a Founding Partner at Selvedge Venture and a Co-Founder and Non-Executive Director at Multiomic Health. With a background in strategy and entrepreneurship, he has made impactful investments in companies like BIOS (Series A) and Exogene (Seed), showcasing his expertise in venture capital and business development within the biotech industry.

Work Experience 

  • Founding Partner

    2019 - Current

    Selvedge Venture is a Venture Capital management and advisory firm with a focus on deep tech in life sciences and healthcare. https://selvedgeventure.com

  • Co-Founder and Non-Executive Director

    2021

    Multiomic Health is a next-generation precision medicine venture, integrating computational systems biology with laboratory science to develop and commercialize new therapeutics for metabolic syndrome — the world’s largest healthcare burden. https://multiomic.health

  • Venture Partner

    2020

    Mubadala Capital is the wholly owned asset management arm of Mubadala Investment Company with over USD$16 billion AUM. Mubadala is an Abu Dhabi sovereign wealth investor with USD$250bn+ AUM. https://www.mubadala.com/en/what-we-do/capital/ventures

  • Venture Partner: Healthcare

    2020

    Ada Ventures is the inclusive venture firm. Ada Ventures finds and funds extraordinary talent building breakthrough ideas for the hardest problems we face. We are investing out of our second fund and we invest £250,000 - £1m in UK technology companies across climate, economic empowerment and healthcare & ageing. If you are raising seed capital for your start-up you can apply directly below: Fundraising: https://adaventures.typeform.com/AdaSubmissions https://www.adaventures.com/

  • Acquisitions and Investments (Advisory)

    2024

    The Ellison Institute of Technology’s mission is to develop and deploy technology in pursuit of solving some of humanity’s most challenging and enduring problems. Guided by world leaders, scientists and entrepreneurs, EIT seeks to accelerate innovation in health and medical science, food security and sustainable agriculture, climate change and clean energy, and government innovation and era of artificial intelligence. https://eit.org

  • Consultant (Advisory)

    2023

    Biotechnology development government advisory work to help build nascent and emerging bio-economies. https://www.institute.global

  • Investor

    2023

    via Mubadala Capital

Metsera develops oral and injectable therapies for obesity and metabolic diseases.

Raised $505,000,000.00 from SymBiosis, Deep Track Capital, Viking Global Investors, Alpha Wave Ventures, T. Rowe Price, Newpath Management, Venrock Healthcare Capital Partners, T. Rowe Price Japan, Google Ventures and Fidelity.

  • Board Observer

    2021

  • Investor/Advisor

    2021

  • Investor/Advisor

    2021

Articles About Alasdair

Relevant Websites